David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“New data – Alessio Cortellinishows that using proton PPIs or ATBs was linked to worse outcomes for stage III NSCLC pts receiving durvalumab (PACIFIC trial) but not those on a placebo. This suggests these common drugs might actually weaken the benefits of ICI. Great collaborative work!”
Title: Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
Authors: Leonardo Brunetti, Valentina Santo, David J. Pinato, Fabrizio Citarella, Sarah Orlando, Fabian Acker, Vittoria Colella, Biagio Ricciuti, Jarushka Naidoo, Amin Nassar, Heather A. Wakelee, Kazuki Takada, Abdul Rafeh Naqash, Marina C. Garassino, Carlo Greco, Sara Ramella, Francesco Pantano, Giuseppe Tonini, Bruno Vincenzi, Bryan Arlunno, Jordi Remon, Claudia Parisi, David Planchard, Benjamin Besse, Antoine Desilets, Bertrand Routy, Arielle Elkrief, Fabrice Barlesi, Lisa Derosa, Alessio Cortellini
Read the Full Article.
Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC?
